Garuda Therapeutics (Garuda), a biotechnology company creating off-the-shelf, HSC therapies for a multitude of blood disorders, today announced the successful completion of an approximately $50 ...

Early approaches focused on the importance of HLA matching, and were an important aspect of deceased organ donor allocation. More recently, and as a direct result of improvements in ...

Two questions directly pertain to the feasibility of such an approach: first, how many such cell lines would be needed for HLA matching to the majority of iPS cell recipients, and second ...

European regulators have cleared Anocca to begin a Phase I/II umbrella trial of its lead targeted T-cell receptor (TCR) therapy ANOC-001 and other pipeline candidates in certain advanced pancreatic ...

The HLA system is the most polymorphic system in ... Finally, the level of sensitivity of antibody detection should match the level of sensitivity utilized to perform the final crossmatch, which ...